Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Investor Presentation (June 2021)
29 slides from Orchid Pharma's investor presentation, Jun 9, 2021
Slide 1: Exchange filing cover letter: correction regarding Investor Presentation
OrchidPharmaY ( Formerly known as Orchid Chemicals & Pharmaceuticals Limited } Corp. Off.: Orchid Pharma Ltd., ‘Orchid Towers’ 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034. India CIN: L24222TN1992PLC022994 June 09, 2021 National Stock Exchange of India Ltd BSE Limited Listing Depar
Slide 2: The Turnaround Story
OrchidPharma” — A Dhanuka Group Company — The Turnaround Story
Slide 3: Company Overview
OrchidPt yarn a? COMPANY OVERVIEW PIONEER IN CEPHALOSPORIN ANTIBIOTICS R&D Focused, Inventor of Enmetazobactam (Ph.-3 Trials done in US & EU) Acquired by Dhanuka Group through CIRP Process on 1st April 2020 ABOUT DHANUKA GROUP ~ 2500 Crore diversified group. interests in Crop Care and Pharma Dhanuka
Slide 4: Company history and milestones
OrchidPharma NS -0e@ e @e- @ 1992 @ 2021 Orchid was Formed Marked Improvement in Performance 6°” @ 2020 First USFDA Approval Dhanuka Acquires Orchid on 31st March 2020 FDF Facility Inaugurated by Dr. APJ Abdul Kalam @ 2008 @ 2019 First ANDA Approval NCLT Approves Dhanuka’s plan Partnership with Merc
Slide 5: Background and Pedigree
OrchidPharma WS — BACKGROUND AND PEDIGREE -0e@ @ee- DHANUKA AGRITECH LTD DHANUKA LABORATORIES LTD. ¢ Flagship of the Group founded in 1980. fe * Pharmaceutical Arm started in 1998. fe ¢ Listed on Stock Exchanges for 35 years with a Market ¢ Leader in Cephalosporin Antibiotics in Emerging markets. Ca
Slide 6: Key Rationale for Acquiring Orchid Pharma
OrchidPharmai SS KEY RATIONALE FOR ACQUIRING ORCHID PHARMA -0e@ e @e- ORCHID DHANUKA GROUP Strengths 1. Regulatory Approvals— US / EU / Strengths Japan / LATAM 1. Cost Efficient Management 2. Large Capacity 2. strong R&D wee 3. Widest Range 3. Execution Capabilities Threats S Weaknesses S 1. Financi
Slide 7: Antibiotics - The Life Saving Drugs
OrchidPharma? — A Diiwke Geonp Comyuis — ANTIBIOTICS - THE LIFE SAVING DRUGS GLOBAL ANTIBIOTICS MARKET SHARE, BY DRUGS CLASS,2019% > Global Antibiotics Market in 2019 — USD 43 bn EO Cephalosporin sascnncncnnncecn sc scnnenceenscnnencnenncecnscscnnennnansnnnnnanannannnansannnansanansnnsnsanananennans
Slide 8: Capabilities
OrchidPharma? — A Diente Geonp Comyruses — CAPABILITIES
Slide 9: Widest Range of Cephalosporins
OrchidPharma? — A Ditka Geonp Comypuss — WIDEST RANGE OF CEPHALOSPORINS GENERATION 4 ORAL . ORAL . Cefadroxi Cefprozil ORAL " Cefalexin Cefuroxime Cefdinir STERILE * Cefradine Cefaitoren Cefepime STERILE » Cefalonium TERT Cefoxitin cefoctoxdme ccthioten Cefquinome Celprrome ereob broke| - Cefalothin
Slide 10: Global Presence with a Wide Customer Base
GLOBAL PRESENCE WITH A WIDE CUSTOMER BASE SANDOZ Mylan) kucernannal een sae: hikma. ‘a (SPfizer ~ a a polpharma | e Olsuka Momenta al seal ~ : ~ oS SANOFI eg STADA SUN Revenue Breakup by Geography Export Market Share by Geography (FY-21) ier) x ay, 9% 2% 6% » s 7% B Africa BAsia North America Africa
Slide 11: Largest Integrated Cephalosporin API Company
hi Pharma? LARGEST INTEGRATED CEPHALOSPORIN API COMPANY ¢ Integrated facilities from Intermediate to finished — 60 Acre ¢ Sterile — 3 Lines Sterile Crystalline and 1 Lyophilized ¢ Oral—7 Blocks with multiple lines ¢ Intermediates — 5 Blocks with multiple lines ¢ Total Capacity 9OOMT ¢ Worldwide appr
Slide 12: Finished Dosage Facilities
OrchidPharma¥ — A Diveke Geen Compares — FINISHED DOSAGE FACILITIES IKKT ¢ USFDA / UKMHRA Certified ¢ 29 ANDAs with associated DMFs ¢ Exporting to US / EU Markets ¢ Now Hived off to associate JV Company Fl ¢ Was a small Cephalosporin Operation ¢ Now being upgraded to meet PICS standards ¢ Will focus
Slide 13: Strong R&D Capabilities
Nae Pharma STRONG R&D CAPABILITIES ANALYTICAL R&D PROCESS R&D NMR (Multinuclear) Sterile Crystallization & Lyophilization OdaA) Chemical Resolution lon Chromatograph Freeze Driers Amino acids and peptide synthesis IGA ORCHID PHARMA HAS BEEN FOCUSED ON R&D, WILL
Slide 14: Board of Directors
OrchidPharma? —A Diwle Geonp Congres -0@ eo @e- BOARD OF DIRECTORS Mr. Ram Gopal Agarwal Mr. Manish Dhanuka Mr. Arun Kumar Dhanuka Mr. Mridul Dhanuka Chairman and Non- Managing Director Non-Executive Director Whole-Time Director Executive Director ~Visionary Leader at the ~Director at DLL, DAL and ~
Slide 15: Focus on ESG
OrchidPharma? — A Piiartnle Geom Company FOCUS ON ESG Environment Consciousness has been Orchid's Of. Hallmark right from Inception. Dupont safety systems implemented with an aim I< 02 ; of Zero Incident 776) 03 Orchid now backed by Dhanuka group, having TARA excellent Corporate Governance Standards
Slide 16: Commitment to Environment
OrchidPharma’ COMMITMENT TO ENVIRONMENT AIR * Advanced Evaporation and RO Systems * Vent Gas Scrubbing System * ZERO Liquid Discharge * Highest Possible Recovery @ -80deg Centigrade « No fugitive Emissions * 70% of fresh Water is recycled after recovery ¢ ESP / Venturi Filters for Particle Arrest
Slide 17: Future Strategy
OrchidPharma? — A Dhanuka Group Company — FUTURE STRATEGY
Slide 18: Strategy for Orchid API Business
OrchidPharma SS STRATEGY FOR ORCHID API BUSINESS WIN BACK LOST BUSINESS GROW NEW BUSINESS DEBT REDUCTION ¢ Bring down term debt to below * ORAL * To develop new products, which Rs. 100 crore by March 2022 * Target old customers in ele already off patent, but notin * Hiving off the NPNC FDF business
Slide 19: Strategy - To Attain Leadership in APIs
OrchidPharma? A Diveimbe Geom Compu STRATEGY - TO ATTAIN LEADERSHIP IN APIS * Business Consolidation Committee formed to evaluate the consolidation of Dhanvuka Laboratories Limited with Orchid. PROPOSALTO CONSOLIDATE GROUP’S API * This consolidation was part of the Resolution Plan suomitted to NCLT
Slide 20: Proud Moment for India: First Product Invented in India to Clear Ph.-3
OrchidPharma? — A Dhanuka Group Company — PROUD MOMENT FOR INDIA me SPee Eee ww Pia I Oe i FIRST PRODUCT INVENTED IN INDIA, TO CLEAR PH.-3 In 2013, Orchid out licensed a NCE Enmetazobactum to Allecra Therapeutics, Germany for Clinical Trials. Cleared the Phase 3 trials in October 2020. This is a Uni
Slide 21: Financials
OrchidPharma? FINANCIALS
Slide 22: Impact of COVID-19
OrchidPharma? A Divtwbe Gevnp IMPACT OF COVID-19 COVID - 19 created Estimated demand In last one year of our takeover, we havoc across the reduction of ~ 20% in have utilized the spare capacity to Pharmaceutical 2020 vs 2019. complete validation batches of supply chain new product filings in Europe
Slide 23: Cost Control Measures Improving Financial Performance
OrchidPharma? COST CONTROL MEASURES IMPROVING FINANCIAL PERFORMANCE -0e@ e @e- IMPROVING PROFITABILITY... ORCHID FINANCIALS PRODUCT-MARKET MIX 600 — 481451 N m Regulated - Oral 400 m= Regulated - Sterile 200 —., = Emerging - Oral ; 9 ] m= Emerging - Sterile m 19-20 m 20-21 Sales EBITDA ...AS A RESUL
Slide 24: Financial Performance (Excluding IKKT Business)
OrchidPharma’ FINANCIAL PERFORMANCE (EXCLUDING IKKT BUSINESS) -©@@ee- (Rs Crs) FY2021 FY2020 Change % Sales 450.70 481.21 -6.34% Other Income!) 6.48 24.28 COGS 229.27 200.31 Employee Expenses 64.40 71.60 Other Expenses 99.14 199.97 EBIDTA (including other income)* 63.64 9.43 574.86% EBITDA Margin (%
Slide 25: Slide 25
Slide 26: Slide 26
Slide 27: Current Corporate Structure and Shareholding of Orchid Pharma Ltd.
NS OrchidPharma Current Corporate Structure Dhanuka Group Dhanuka Laboratories Ltd. Public Dhanuka Agritech Ltd. (Unlisted) Public & Others Current Shareholding of Orchid Pharma Ltd. SH Summary (%) No. of Shares Holding (%) Promoters 4,00,15,963 98.04% Financial Institutions/ Banks 3,94,785 0.97% In
Slide 28: CSR Initiatives
OrchidPharma CSR INITIATIVES SH As a global pharmaceutical corporation, company's desire to cure extends beyond health care, spilling over to ills in the social and economic arenas This sensitivity to the community related issues has spurred into creating a development trust, which has embarked on a
Slide 29: Awards and Accolades
hidPharma? i AWARDS AND ACCOLADES Top Indian Public Limited Company in Patent at the 5th National Intellectual ras ere me Canara mecee WA) Property Award 2013, for its meritorious export performance by organized by Cll The Tamil Chamber of Commerce, Chennai Conferred with the Export Excellence Alath